



RBWH / MNHHS / Cancer Care Services


CCS GP Day 2025

Clinical Trials and GPs – Working Together to Achieve Success

Integrated CAncer REsearch Collaborative (I-CARE), CCS


Amy Ives RN, Grad Cert Clinical Trials Practice
Nurse Manager Clinical Trials, I-CARE

I-CARE Research activity – as at 23/4/2025 :



Current Studies				
	Medical Oncology	Haem BMT	Radiation Oncology	Total
EOI/Feasibility	24	33	15	72
Pending	20	7	4	31
Recruiting	44	31	8	83
Follow Up	79	27	15	121
Total	167	98	42	307

I-CARE Research activity – as at 23/4/2025 :



Patients Registered					
	Medical Oncology	Haem BMT	Radiation Oncology	Total	
2020	287	35	62	384	
2021	445	125	45	615	
2022	391	66	35	492	
2023	373	107	27	507	
2024	223	90	42	355	
2025	86	29	12	127	
Total	1805	452	223	2480	

Collaboration and Communication between GP and Trials Team

Patient Suitability and Referral Pathway

Trial Specific Details

Support of Patients Participating in Trials

Financial and Practical Considerations

Patient Suitability & Referral Pathway

- Inclusion/Exclusion Criteria
- Referrals

[Home](#) / [Refer your patient](#) / Cancer Care Services

Cancer Care Services

Conditions

- [Brain tumours](#)
- [Breast Cancer](#)
- [Cervical Cancer](#)
- [Colorectal Cancer](#)
- [Endometrial Cancer](#)
- [Gastro-Oesophageal Cancer](#)
- [Head and Neck Cancer](#)
- [Hepatocellular \(Liver\) Cancer](#)
- [Lung Cancer](#)
- [Melanoma](#)
- [Ovarian Cancer](#)
- [Pancreatic-biliary Cancer](#)
- [Prostate Cancer](#)
- [Sarcoma \(Bone or Soft tissue\) Cancer](#)
- [Testicular Cancer](#)

Send referral

Hotline: 1300 364 938

Electronic:

[GP Smart Referrals \(preferred\)](#)

[eReferral system templates](#)

Medical Objects

ID: MQ40290004P

HealthLink EDI: qldmnhhs

Trial Specific Details

- Patient Information & Consent Form (PICF)
- [ClinicalTrials.gov](https://clinicaltrials.gov), or ANZ Clinical Trials Registry ([ANZCTR](https://anzctr.org.au))
- CCS Webpage via MNH: metronorth.health.qld.gov.au/hospitals-services/cancer-care-services/clinical-trials

Lung	MK-2870-019	A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery	TPCH
Lymphoma	Kite Pharma KT-US-656-0601	A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma	RBWH
Lymphoma	PMCC EpLCART Study	A Phase II Open-Label, Multi-Centre Study of Minimal ResidualDisease-Directed Consolidation with Epcoritamab orEpcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)	RBWH

Support of Patients Participating in Trials

- Consultant Letters to GPs
- Clinical Trial Coordinators
 - Specialist Oncology Nurses point of contact
 - Nursing assessments to help identify adverse events
 - Requests to GP for information, basic assessments
 - Blood tests, observations, urinalysis, standard medications
- Shared Care Models
 - Survivorship
 - Shared Care Clinical Trials



Financial and Practical Considerations



Travel and Accommodation Support

Commercially Sponsored vs Non-Commercial
Trials

Patient Transport Subsidy Scheme (PTSS)



Practical Considerations

Additional visits, tests
Pressure on families, jobs



Thanks and Acknowledgments:

- I-CARE Clinical & Operations Teams
 - Jacqui Keller, I-CARE Operations Manager
- CCS Consultants & Investigators